• Molecular NameCefuroxime
  • SynonymCefuroxim; Cefuroxime [USAN:BAN:INN]; Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]
  • Weight424.39
  • Drugbank_IDDB01112
  • ACS_NO55268-75-2
  • Show 3D model
  • LogP (experiment)-0.921
  • LogP (predicted, AB/LogP v2.0)-0.05
  • pkaN/A
  • LogD (pH=7, predicted)-3.86
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.11
  • LogSw (predicted, AB/LogsW2.0)1.83
  • Sw (mg/ml) (predicted, ACD/Labs)0.36
  • No.of HBond Donors4
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds8
  • TPSA199.06
  • StatusFDA approved
  • Administrationoral, intramuscular, intravenous
  • PharmacologyA second-generation cephalosporin antibiotic that has been widely available in the USA as Ceftin since 1977.
  • Absorption_value44.5
  • Absorption (description)Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
  • Caco_2N/A
  • Bioavailability32.0
  • Protein binding50.0
  • Volume of distribution (VD)0.20 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsm axetil moiety is metabolized to acetaldehyde and acetic acid
  • Half life1.7 h
  • ExcretionUrine 66-100% Unchanged
  • Urinary Excretion96
  • Clerance0.94CLcr + 0.28
  • ToxicityAllergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A